Biotech News

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

Organogenesis (ORGO)OrganogenesisClinical readout

CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced published results from a prospective, multicenter,

Related news

Organogenesis

Regenerative Medicine Organogenesis develops and manufactures regenerative-medicine products used to support healing in difficult wounds and surgical procedures. Advanced Wound Care The company's wound-care portfolio includes cellular and tissue-based products, placental-derived products and other biologic matrices used in chronic and...

Recent company news

Stock data

Close
2.41 USD
Market cap
288.23M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States